Navigation Links
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK

COPENHAGEN, Denmark, July 28 /PRNewswire/ -- Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline.

The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads. These technologies were developed by Nuevolution and Praecis Pharmaceuticals, a wholly owned subsidiary of GlaxoSmithKline.

Under the terms of the cross-licensing agreement, GlaxoSmithKline will obtain a non-exclusive license under technology patents of Nuevolution, and Nuevolution will obtain a one time license fee and a non-exclusive license under technology patents of GlaxoSmithKline.

Further details of the agreement are not disclosed.

"By entering into this agreement, both companies are offered an optimal basis for continued development and application of the technologies" said Allen Oliff, SVP Molecular Discovery Research of GSK and Alex Gouliaev, CEO of Nuevolution A/S continued "our innovative technologies allow small molecule hit and lead discovery at an unprecedented scale. This agreement secures both companies the rights to operate these powerful technologies to their fullest extent".

About Nuevolution

Nuevolution is a leading lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based lead discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing lead discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Invest and Novo A/S. For more information about Nuevolution A/S, please visit the company's website

    For further information please contact:

    Nuevolution A/S
    Alex Haahr Gouliaev, CEO
    T: +45-70-20-09-87

SOURCE Nuevolution A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
2. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
3. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
4. SEQUENOM Announces Launch of MassARRAY Compact 96 System
5. Human Genome Sciences Announces Proposed Public Offering of Common Stock
6. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
7. Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
10. Spectrum Announces Fetal Bovine Serum Product Line
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
Breaking Biology News(10 mins):